Trial Profile
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Glandular and epithelial neoplasms; Neuroendocrine carcinoma; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Registrational
- Acronyms SAUL
- Sponsors Roche
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 22 Dec 2022 This trial has been completed Belgium, according to European Clinical Trials Database record.
- 21 Dec 2022 Status changed from active, no longer recruiting to completed.